Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 5Recruiting 4Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 4Breast 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 5Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 4Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Renal Cell 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Childhood Solid Tumors 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Adenocarcinoma 1Advanced Solid Tumor 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasms × talazoparib × Clear all
NCT03343054 2024-08-22

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Pfizer

Phase 1 Completed
28 enrolled 43 charts
Breast

Breast Neoplasms, Neoplasms

NCT04635631 2023-10-10

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Pfizer

Phase 1 Completed
15 enrolled 38 charts
Tumor-Agnostic

Neoplasms

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Completed
2,336 enrolled
Tumor-Agnostic

Neoplasms

NCT02921919 2022-08-24

Open-Label Extension and Safety Study of Talazoparib

Pfizer

Phase 2 Completed
120 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

University Hospital, Caen

Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡